Search Tag: abionic
2024 28 Nov
Abionic, an innovative medical diagnostics company specialising in rapid early detection technologies, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IVD CAPSULE PSP test. Abionic, an emerging medical diagnostics company focused on rapid early detection technologies, received 510(k) clearance for...Read more
2024 02 Oct
Abionic, an emerging medical diagnostics company focused on rapid early detection technologies, announced today that its IVD CAPSULE PSP test has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to accelerate the Time-to-Detection of Sepsis. Already certified under the EU IVDR as of July 2022, this FDA clearance marks...Read more
2024 22 Feb
Abionic SA, a Swiss leader in nanofluidic point-of-care diagnostic solutions, is thrilled to announce the appointment of Patrick Pestalozzi as its new Chief Executive Officer, effective April 1st, 2024. A former Management Consultant, Silicon Valley executive, and Entrepreneur, Patrick brings to Abionic 3 decades of global experience, more...Read more
2023 26 Oct
Fapon, a leading life sciences company, entered into a strategic cooperation agreement with two Swiss biotech companies LASCCO SA and Abionic SA, that granted Fapon an exclusive license to utilize the pancreatic stone protein (PSP) biomarker for sepsis diagnosis in China. This strategic partnership will enable Fapon to engage in the research, development,...Read more
2023 13 Jun
Rapid Diagnostic Test that could save millions of lives At Swiss Medtech Day, the most important event in the Swiss medical technology industry with around 700 attendees, Lausanne-based company Abionic, founded in 2010, was presented with the Swiss Medtech Award valued at CHF 75,000. Abionic specialises in providing rapid diagnostic tests...Read more
2022 01 Nov
On September 21st during the Clinical Chemistry congress on Jönköping, Sweden, Dr. Francois Ventura, Intensive Care Physician and Chief Medical Officer gave an academic lecture addressing the disease burden of sepsis and antimicrobial resistance (AMR), and the place of biomarkers in the management of sepsis and how they could help improve the management...Read more
2022 18 Oct
The role of Point-of-Care Testing in the Early Identification and Management of Sepsis Introduction & Welcome On September 22nd, over 240 attendees from all over the world had the opportunity to connect and tune into this educational session along with interactive roundtable discussions, chaired and moderated by Prof. Jean-Louis Vincent,...Read more
2022 14 Oct
The problem of antimicrobial resistance and the use of a clinical decision score and point-of-care testing biomarkers, such as CRP and PSP, to help solve this problem. Introduction Infectious diseases are a public health issue around the world, with bacterial, viral, parasitic, or fungal-related diseases responsible for 26% of mortality...Read more
2022 11 Oct
The Global Sepsis Alliance (GSA) and the Sepsis Stiftung joined together to celebrate 10 years of World Sepsis Day on 16 September 2022 in Berlin, under the theme of " Making Sepsis a National and Global Health Priority ”. The event aimed to engage with high-level policy makers, representatives of health authorities, patient organizations, health...Read more
2022 16 Sep
Hybrid Event On September 16, 2022, the Global Sepsis Alliance and the Sepsis Stiftung will join forces to host a unique event celebrating a decade of World Sepsis Day – both in person in Berlin, as well as live streamed on this website. The event is split up into 3 parts – a scientific symposium with renowned speakers from all over the...Read more
2022 05 Sep
World Sepsis Day was inaugurated exactly ten years ago and, since then, has made great progress in the fight against sepsis. Sepsis awareness has increased across the globe. However, sepsis still accounts for approximately 11 million lives lost every year around the world. This does not include millions of deaths by viral sepsis due to COVID-19. ...Read more
2022 09 Aug
BSI certification agency has granted Abionic’s abioSCOPE® device and PSP test the IVDR certification for in-vitro diagnostics. This certification complies with Europe’s new In-vitro Diagnostic Regulation (IVDR), and will be required for products sold within the EU from May 2022 onward. A transitional regulation allows established, non-IVDR-certified...Read more
2022 09 Aug
BSI certification agency has granted Abionic’s abioSCOPE® device and PSP test the IVDR certification for in-vitro diagnostics. This certification complies with Europe’s new In-vitro Diagnostic Regulation (IVDR), and will be required for products sold within the EU from May 2022 onward. A transitional regulation allows established, non-IVDR-certified...Read more
2022 06 Jun
1. Sepsis: the Need for Speed Sepsis is a life-threatening form of organ dysfunction caused by a dysregulated host response to infection 1 . This extremely heterogeneous and dynamic syndrome is the result of complex interactions between invading microorganisms and the host’s immune system. Disruption of the host’s ability to maintain immune homeostasis...Read more
2022 21 Apr
Based in Switzerland, Abionic is an in vitro diagnostic company, uniquely positioned at the intersection of medical technology, biotechnology and nanotechnology. The company has developed an unparalleled nanofluidic technology-based platform, the abioSCOPE® to offer patients fast blood test results right at the Point-of-Care (PoC). The abioSCOPE® is...Read more
2021 28 Jul
Context Growing numbers of obesity, alcohol abuse and gallstones are leading to an increase in the incidence of acute pancreatitis. This sudden inflammatory disease of the pancreas usually requires hospitalization due to high mortality and morbidity rates. In some cases, acute pancreatitis can progress to severe pancreatitis, which is characterized...Read more
2021 28 May
Critical Care, the top-ranked open access journal in the field of critical care medicine, published the results of a study led by Lausanne University Hospital’s Dr Philippe Eggimann and Bern University Hospital’s Dr Yok-Ai Que this month [1]. The authors analyzed pooled data from five cohorts showing that the Pancreatic stone protein (PSP) biomarker...Read more
2021 08 Apr
On April 6th, Abionic and Palex joined forces to participate in the first day of GaliSepsis, the National Sepsis Course hosted and organized virtually by the Ourense University Hospital Complex (CHUO) in Spain. With the aim of updating the most important concepts and reviewing the latest developments in the management of patients with sepsis, three...Read more
2021 08 Apr
On April 6th, Abionic and Palex joined forces to participate in the first day of GaliSepsis, the National Sepsis Course hosted and organized virtually by the Ourense University Hospital Complex (CHUO) in Spain. With the aim of updating the most important concepts and reviewing the latest developments in the management of patients with sepsis, three...Read more
2020 17 Nov
Speakers Prof. Dr Steven Opal Alpert Medical School of Brown University, USA Dr Bruno Francois Centre Hospitalier Universitaire de Limoges, France Dr Angelo Giacomucci Unita di Terapia Intensiva, Azienda Ospedaliera di Perugia, Italy Dr Phillipe Eggimann Centre Hopsitalier Universitaire Vaudois, Switzerland Find Abionic on Social...Read more